Anxiety, depression and stress during the COVID-19 pandemic: Results from a cross-sectional survey.


Journal

Journal of psychiatric research
ISSN: 1879-1379
Titre abrégé: J Psychiatr Res
Pays: England
ID NLM: 0376331

Informations de publication

Date de publication:
05 2021
Historique:
received: 21 09 2020
revised: 05 02 2021
accepted: 23 02 2021
pubmed: 6 3 2021
medline: 11 5 2021
entrez: 5 3 2021
Statut: ppublish

Résumé

Multiple survey studies have demonstrated a mental health (MH) burden of COVID-19 globally. However, few studies have examined relevant risk factors for pandemic-related MH issues. A link to an online survey was posted from April 8th - June 11th, 2020 which included questions regarding COVID-19 experience, perceived impact of the pandemic on life domains (e.g., social communication, finances), behavioural alterations (e.g., online activities, substance use), and MH treatment history. Current psychiatric symptom severity and impairment were evaluated using the Generalized Anxiety Disorder-7, Patient Health Questionnaire-9, and the Perceived Stress Scale. Overall, 632 individuals (82% female, mean age:42.04 ± 16.56) in Canada and the United States completed the survey. While few reported contracting COVID-19 (0.5%), the impact of the pandemic was evident, with a vast majority reporting anxiety around COVID-19 infecting loved ones (88%). Almost half (43%) reported previous MH treatment and 31% met criteria for GAD, 29% for MDD and 63% reported significantly high levels of stress. Female sex, younger age and past MH treatment emerged as significant predictors of these issues(p < .01). Age-related differences in the impact of COVID-19 on life domains, substance use, and online activity were also noted. The findings from the current sample add to the growing literature suggesting negative effects of COVID-19 on MH, while highlighting specific risk factors. Age may be an important factor in predicting MH during this pandemic.

Sections du résumé

BACKGROUND
Multiple survey studies have demonstrated a mental health (MH) burden of COVID-19 globally. However, few studies have examined relevant risk factors for pandemic-related MH issues.
METHODS
A link to an online survey was posted from April 8th - June 11th, 2020 which included questions regarding COVID-19 experience, perceived impact of the pandemic on life domains (e.g., social communication, finances), behavioural alterations (e.g., online activities, substance use), and MH treatment history. Current psychiatric symptom severity and impairment were evaluated using the Generalized Anxiety Disorder-7, Patient Health Questionnaire-9, and the Perceived Stress Scale.
RESULTS
Overall, 632 individuals (82% female, mean age:42.04 ± 16.56) in Canada and the United States completed the survey. While few reported contracting COVID-19 (0.5%), the impact of the pandemic was evident, with a vast majority reporting anxiety around COVID-19 infecting loved ones (88%). Almost half (43%) reported previous MH treatment and 31% met criteria for GAD, 29% for MDD and 63% reported significantly high levels of stress. Female sex, younger age and past MH treatment emerged as significant predictors of these issues(p < .01). Age-related differences in the impact of COVID-19 on life domains, substance use, and online activity were also noted.
CONCLUSION
The findings from the current sample add to the growing literature suggesting negative effects of COVID-19 on MH, while highlighting specific risk factors. Age may be an important factor in predicting MH during this pandemic.

Identifiants

pubmed: 33667763
pii: S0022-3956(21)00137-0
doi: 10.1016/j.jpsychires.2021.02.059
pmc: PMC8548032
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

96-103

Informations de copyright

Copyright © 2021. Published by Elsevier Ltd.

Références

J Clin Psychiatry. 2004;65 Suppl 1:37-43
pubmed: 14728095
Ann Intern Med. 2020 Nov 3;173(9):767-770
pubmed: 32598162
JAMA. 2020 Dec 8;324(22):2253-2254
pubmed: 33216114
Health Rep. 2020 Jul 15;31(6):3-11
pubmed: 32672923
Psychol Med. 2010 Feb;40(2):225-37
pubmed: 19531277
Psychopharmacol Bull. 1993;29(2):321-6
pubmed: 8290681
Psychiatry Res. 2020 Jun;288:112954
pubmed: 32325383
Qual Life Res. 2007 Feb;16(1):17-29
pubmed: 17036252
Arch Intern Med. 2006 May 22;166(10):1092-7
pubmed: 16717171
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Dialogues Clin Neurosci. 2015 Sep;17(3):327-35
pubmed: 26487813
Soc Sci Med. 2019 Jul;233:181-192
pubmed: 31207470
J Sleep Res. 2020 Aug;29(4):e13074
pubmed: 32410272
Front Neuroendocrinol. 2014 Aug;35(3):320-30
pubmed: 24887405
JAMA Intern Med. 2020 Jun 1;180(6):817-818
pubmed: 32275292
Ann Epidemiol. 2020 Jul;47:37-44
pubmed: 32419766
Psychiatry Res. 2020 Aug;290:113112
pubmed: 32460185
Psychiatr Serv. 2008 Jan;59(1):91-5
pubmed: 18182545
J Anxiety Disord. 2008 Oct;22(7):1128-36
pubmed: 18182275
J Health Soc Behav. 1983 Dec;24(4):385-96
pubmed: 6668417
Nutrients. 2020 May 28;12(6):
pubmed: 32481594
Cad Saude Publica. 2020 Apr 30;36(4):e00054020
pubmed: 32374806
Lancet Psychiatry. 2020 Jun;7(6):547-560
pubmed: 32304649
J Psychiatr Ment Health Nurs. 2011 Oct;18(8):744-50
pubmed: 21896118
Nutrients. 2020 Jul 19;12(7):
pubmed: 32707724
J Gerontol B Psychol Sci Soc Sci. 2021 Jan 18;76(2):e24-e29
pubmed: 32470120
Qual Life Res. 2014 Apr;23(3):907-16
pubmed: 24062242
Int J Environ Res Public Health. 2020 Mar 19;17(6):
pubmed: 32204411
Psychiatry Res. 2020 Jun;288:112936
pubmed: 32276196
Psychother Psychosom. 2020;89(4):242-250
pubmed: 32272480
Psychol Aging. 1987 Jun;2(2):171-84
pubmed: 3268206
JAMA Netw Open. 2020 Sep 1;3(9):e2021892
pubmed: 32975575
Aging Ment Health. 2006 May;10(3):298-302
pubmed: 16777658
Brain Behav Immun. 2020 Jul;87:49-50
pubmed: 32304883
Acta Biomed. 2020 Mar 19;91(1):157-160
pubmed: 32191675
Psychol Trauma. 2020 Aug;12(S1):S17-S21
pubmed: 32496100
PLoS One. 2020 Apr 16;15(4):e0231924
pubmed: 32298385
Psychol Health Med. 2021 Jan;26(1):13-22
pubmed: 32223317
Brain Behav Immun. 2020 Jul;87:56-58
pubmed: 32315758
Lancet Public Health. 2020 May;5(5):e256
pubmed: 32199471
JAMA Netw Open. 2020 Mar 2;3(3):e203976
pubmed: 32202646
J Med Virol. 2020 May;92(5):473-475
pubmed: 32048740
JAMA. 2020 Jul 7;324(1):93-94
pubmed: 32492088
JMIR Public Health Surveill. 2020 Sep 18;6(3):e19630
pubmed: 32589149
CMAJ. 2004 Mar 2;170(5):793-8
pubmed: 14993174
Asian J Psychiatr. 2020 Jun;51:102076
pubmed: 32334409
Psychol Trauma. 2020 Aug;12(S1):S236-S238
pubmed: 32525380
Can J Psychiatry. 2007 Apr;52(4):233-40
pubmed: 17500304
Brain Behav Immun. 2020 Jul;87:75-79
pubmed: 32325098
J Child Psychol Psychiatry. 2020 Aug;61(8):875-889
pubmed: 32634259
J Stud Alcohol Drugs. 2018 May;79(3):423-431
pubmed: 29885150

Auteurs

Jasmine Turna (J)

Michael G DeGroote Centre for Medicinal Cannabis Research and Peter Boris Centre for Addictions Research, McMaster University, Hamilton, ON, Canada; Department of Psychiatry and Behavioural Neurosciences, McMaster University, Canada; MacAnxiety Research Centre, McMaster University MacAnxiety Research Centre, McMaster University, Hamilton, ON, Canada.

Jasmine Zhang (J)

MacAnxiety Research Centre, McMaster University MacAnxiety Research Centre, McMaster University, Hamilton, ON, Canada.

Nina Lamberti (N)

MacAnxiety Research Centre, McMaster University MacAnxiety Research Centre, McMaster University, Hamilton, ON, Canada.

Beth Patterson (B)

Department of Psychiatry and Behavioural Neurosciences, McMaster University, Canada; MacAnxiety Research Centre, McMaster University MacAnxiety Research Centre, McMaster University, Hamilton, ON, Canada.

William Simpson (W)

Department of Psychiatry and Behavioural Neurosciences, McMaster University, Canada; MacAnxiety Research Centre, McMaster University MacAnxiety Research Centre, McMaster University, Hamilton, ON, Canada; Winterlight Labs, Toronto, ON, Canada.

Ana Paula Francisco (AP)

Department of Psychiatry and Behavioural Neurosciences, McMaster University, Canada; MacAnxiety Research Centre, McMaster University MacAnxiety Research Centre, McMaster University, Hamilton, ON, Canada.

Carolina Goldman Bergmann (CG)

Department of Psychiatry and Behavioural Neurosciences, McMaster University, Canada; MacAnxiety Research Centre, McMaster University MacAnxiety Research Centre, McMaster University, Hamilton, ON, Canada.

Michael Van Ameringen (MV)

Department of Psychiatry and Behavioural Neurosciences, McMaster University, Canada; MacAnxiety Research Centre, McMaster University MacAnxiety Research Centre, McMaster University, Hamilton, ON, Canada. Electronic address: vanamer@mcmaster.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH